echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > The Lancet Neurol: Association of soluble TREM2 with other markers of autosomal dominant Alzheimer's disease and cognitive function

    The Lancet Neurol: Association of soluble TREM2 with other markers of autosomal dominant Alzheimer's disease and cognitive function

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Therapeutic modulation of TREM2-dependent microglial function may provide additional strategies to slow Alzheimer's disease progression
    .


    Although studies in animal models suggest that TREM2 is protective against Alzheimer's disease , its impact on tau pathology and its potential beneficial effects in Alzheimer's disease patients remain unclear


    TREM2 is protective against Alzheimer's disease

    The aim of this study was to investigate the dynamics of soluble TREM2 (as a biomarker of TREM2 signaling) and amyloid beta (aβ) deposition, taue-related pathology, neuroimaging during autosomal dominant Alzheimer's disease progression Correlations between biological markers and cognitive decline
    .

    Researchers conducted a longitudinal analysis of data from the Dominant Alzheimer's Disease Network (DIAN) observational study, with participants 18 years of age and older recruited between January 1, 2009, and July 31, 2019.
    Patients with a family history of dominant Alzheimer's disease were divided into mutation carriers (n=155) and non-carriers (n=93) according to the pathogenic mutations in PSEN1, PSEN2 and APP genes
    .


    Cerebrospinal fluid (CSF) samples from asymptomatic participants were tested for soluble TREM2 every two years


    Changes in soluble TREM2 levels during pathogenesis in patients with and without pathogenic variants

    In patients with the pathogenic variant, a higher baseline amyloid burden was the only predictor of the annual rate of increase in subsequent increases in soluble TREM2
    .


    In presymptomatic carriers of the pathogenic variant, an increased annual rate of soluble TREM2 was associated with a reduced rate of amyloid deposition


    In patients with the pathogenic variant, a higher baseline amyloid load was the only predictor of the annual rate of increase in subsequent increases in soluble TREM2 In patients with the pathogenic variant, a higher baseline amyloid load was The only predictor of the annual rate of increase in subsequent increases in soluble TREM2 in asymptomatic carriers of a pathogenic mutation with an annual rate of increase in soluble TREM2 below the median, the annual rate of increase in p-tau in the CSF correlates with PiB-PET signal There is a correlation between the annual growth rate of p-tau in the CSF and the annual growth rate of PiB-PET signal in asymptomatic carriers of a pathogenic mutation with a below-median annual growth rate of soluble TREM2 There is a certain correlation between

    Association of p-tau, t-tau, and PiB-PET with the growth rate of soluble TREM2 in carriers of pathogenic variants

    In addition, there was an inverse correlation between cerebrospinal fluid Aβ42 and PiB-PET uptake in pathogenic variant carriers with higher or lower rates of soluble TREM2 growth than the median, assessed longitudinally
    .


    Finally, asymptomatic carriers of the pathogenic variant had increased annual increases in soluble TREM2 with reduced precuneus cortical contraction (r=0.


    An inverse correlation exists between CSF Aβ42 and PiB-PET uptake in pathogenic variant carriers with a higher or lower rate of soluble TREM2 than the median pathogenic variant carrier with a higher or lower rate of soluble TREM2 Inverse correlations between cerebrospinal fluid Aβ42 and PiB-PET uptake in variant carriers

    Taken together, our findings suggest that in autosomal dominant Alzheimer's disease, TREM2 responses immediately appear in the amyloid cascade following pathological changes in Aβ aggregation , further supporting the role of TREM2 in Aβ plaque deposition and deposition.
    role in compaction
    .


    Furthermore, these findings support a beneficial effect of TREM2 on Aβ deposition, Aβ-dependent tau pathology, cortical atrophy, and cognitive decline


    In autosomal dominant Alzheimer's disease, the TREM2 response appears in the amyloid cascade immediately following pathological changes in Aβ aggregation In autosomal dominant Alzheimer's disease, once pathological changes in Aβ aggregation occur , the TREM2 response occurs immediately in the amyloid cascade

    Original source:

    Original source:

    Morenas-Rodríguez Estrella,Li Yan,Nuscher Brigitte et al.


    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational studyLeave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.